Last reviewed · How we verify
HP-HMG
At a glance
| Generic name | HP-HMG |
|---|---|
| Also known as | Menopure, Menopur, Menopur 600 IU, Meriofert, Menopure |
| Sponsor | University of Aarhus |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Follitropin Delta and Follitropin Alfa in Combination With Menotropin
- Retrospective Study of High Dose Follitropin Delta in a Mixed Protocol With Human Chorionic Gonadotropin
- Menopur And Rekovelle Combination Study Version 2.0 (PHASE2)
- Testosterone TRANSdermal Gel for Poor Ovarian Responders Trial (PHASE3)
- Second Phase of the Pilot Study for Obtaining Mature Oocytes by in Vitro Maturation in Oocyte-donor Women (NA)
- Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo Transfer
- Type of Gonadotropin and Embryo Kinetics of Development (PHASE4)
- MEDAM (Menopur Retrospective Data prograM)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HP-HMG CI brief — competitive landscape report
- HP-HMG updates RSS · CI watch RSS
- University of Aarhus portfolio CI